AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 MAR 7 - (NewsRx.com & NewsRx.net) --
by Michelle Marble, staff medical writer -- Intratumoral injection of autologously-derived dendritic cells (DCs) had anti-tumor activity against metastatic cancers, researchers report.
"DCs are potent initiators of immune responses, and the infiltration of DCs into tumors may confer an improved prognosis," said P.L. Triozzi and colleagues, University of Alabama. "Whether the injection of DCs directly into tumors can mediate biologic activity was examined."
"Patients with metastatic dermal or subcutaneous tumors received granulocyte-macrophage-colony stimulating factor to increase the numbers of peripheral blood monocyte precursors," continued the authors. "DCs were then generated from monocytes obtained by phlebotomy with granulocyte-macrophage-colony stimulating factor and interleukin-4 in autologous plasma."
The researchers injected the patients' tumors at multiple sites with 30 million autologous DCs per tumor. The study included seven patients with metastatic melanoma and three patients with metastatic breast carcinoma. All of the patients tolerated the injections well.
Tumor regression was observed in the injected tumors of four of the melanoma patients and two of the breast carcinoma patients. The tumor regression began as early as four days after the tumors were injected with the DCs.
Examination of biopsies from the regressing lesions showed lymphocyte infiltration that was associated with DCs and necrosis. The researchers did not find evidence of neutrophils or macrophages ("Intratumoral ...